Triumeq

ViiV Healthcare Company🇺🇸 United States

FDA Page

Effective Date: Jun 15, 2023
Approval ID: 2997739a-aa91-42aa-a206-a70e2db7b84f
Products: 2 registered
Version: 25

Regulatory Information

Labeling Type

HUMAN PRESCRIPTION DRUG LABEL

Status

Approved

Full Title

These highlights do not include all the information needed to use TRIUMEQ and TRIUMEQ PD safely and effectively. See full prescribing information for TRIUMEQ and TRIUMEQ PD. TRIUMEQ (abacavir, dolutegravir, and lamivudine) tablets, for oral useTRIUMEQ PD (abacavir, dolutegravir, and lamivudine) tablets for oral suspension Initial U.S. Approval: 2014

Quick Stats

Total Products2

Labelers2

Label Sections25

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.